Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty

Mostrar otras versiones (1)

A 78-year-old man came to our attention after undergoing coronary computed tomography angiography documenting multivessel coronary artery disease. He was started on treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab 140 mg subcutaneously every 2 weeks. Trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Fogacci, Federica, Borghi, Claudio, Di Micoli, Antonio, Cicero, Arrigo F. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398460/
https://www.ncbi.nlm.nih.gov/pubmed/34441063
http://dx.doi.org/10.3390/medicina57080857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398460/
https://www.ncbi.nlm.nih.gov/pubmed/34441063
http://dx.doi.org/10.3390/medicina57080857

Ejemplares similares